• Glioblastoma
  • CME

  • Glioblastoma: Current Perspectives, Clinical Challenges and Trends in Treatment

  • Author(s)/Faculty: Terri S. Armstrong, PhD, MS, APRN, BS; Minesh P. Mehta, MD; Mark R. Gilbert, MD; Kenneth Aldape , MD
    Source: HemOnc Today
    Type: Multimedia Articles/Items: 1
    Release Date: 9/28/2011 Expiration Date: 9/27/2012
    Credit Type: CME Number of Credit(s): 0.75
    Cost: Free Provider: Vindico Medical Education
  • Glioblastoma (GBM), the most common primary malignant brain tumor, historically has had an overall poor prognosis, despite surgical resection and external beam radiotherapy. The addition of temozolomide chemotherapy, both concurrent with radiation and as additional adjuvant treatment, improved overall survival. Methylguanine methyltransferase (MGMT) activity may impact response to temozolomide, and increasing dose intensity has been postulated to improve response in both MGMT-expressing (MGMT promoter unmethylated) and MGMT non-expressing (MGMT promoter methylated) tumors. This CME video highlights the findings from the recently released RTOG 0525 clinical trial, which compared the efficacy of standard vs. intensified dosing of temozolomide in the treatment of GBM. In addition, RTOG 0525 explored patient-reported outcomes (neurocognitive testing, quality of life metrics, and patient symptoms/toxicity). Study participants outline those key findings. Finally, faculty discuss the impact of molecular testing of tumor samples and its role in patient stratification for optimal therapy and improved prognosis.

Sponsorship Statement: This continuing education activity is jointly sponsored by HemOnc Today and Vindico Medical Education.

Support Statement: This activity is supported by an educational grant from .

Target Audience: This program is designed for medical oncologists, surgical oncologists, hematologists/oncologists, oncology nurses, and other healthcare professionals involved in the treatment of patients with glioblastoma.

Learning Objectives: At the conclusion of this activity participants should be able to:

  • Understand the use of temozolomide (its drug category) in the management of newly diagnosed glioblastoma.
  • Apply findings of the investigative RTOG 0525 clinical trial to neuro-oncology clinical practice.
  • Explain the longitudinal impact of combination chemotherapy/radiation therapy on newly diagnosed glioblastoma patients.
  • Describe the applicability of molecular studies in glioblastoma case management.

Course Chair:
Mark R. Gilbert, MD
Professor, Department of Neuro-Oncology
Division of Cancer Medicine
The University of Texas M.D.
Anderson Cancer Center
Houston, Texas

Faculty:
Kenneth D. Aldape, MD
Associate Professor
Department of Pathology, M.D.
Anderson Cancer Center
Houston, Texas

Terri S. Armstrong, PhD, MS, APRN, BS
Associate Professor and John S. Dunn Distinguished Professor in Oncology Nursing, UTHSC-SON
Adjunct Associate Professor
Department of Neuro-Oncology, M.D.
Anderson Cancer Center,
Houston, Texas

Minesh P. Mehta, MD
Professor, Radiation Oncology
Northwestern University
Feinberg School of Medicine

External Reviewer:
Roger Stupp, MD

Accreditation:
This educational activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of HemOnc Today® and Vindico Medical Education. Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Vindico Medical Education designates this enduring material activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For the purpose of recertifying with ANCC, AMA PRA Category 1 CME Credit(s)TM from organizations accredited by ACCME can be used.

This enduring material is approved for 1 year from the date of original release, September 28, 2011 to September 27, 2012.

How To Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, watch and listen to the presentations, complete the posttest and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)TM certificate.

Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears on this page and the next page.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Planning Committee and Faculty members report the following relationship(s):
Mark R. Gilbert, MD
Consulting Fees: Genentech, Merck & Co, Abbott.

Kenneth D. Aldape, MD
No relevant financial relationships to disclose.

Terri S. Armstrong, PhD, MS, APRN, BS
No relevant financial relationships to disclose.

Minesh P. Mehta, MD
Receipt of Intellectual property rights/patent holder: Procertus; Consulting Fees: Merck & Co
Fees for Non-CME services received directly from commercial agents or their agents: Pharmacyclics
Ownership Interest: Tomotherapy; Pharmacyclics.

External Reviewer reports the following relationship(s):
Roger Stupp, MD
Advisory Boards: Actelion, Roche, MSD (Merck & co), Merck Serono (EMD).

HemOnc Today® and Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-848-1000; Fax: 856-848-6091. Printed in the USA. Copyright © 2011 SLACK Incorporated®. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education and HemOnc Today® continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education and HemOnc Today®. Neither Vindico Medical Education, HemOnc Today®, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.